ADC Therapeutics Valuation
Is ADCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ADCT?
Other financial metrics that can be useful for relative valuation.
|What is ADCT's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ADCT's PS Ratio compare to its peers?
|ADCT PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ATRA Atara Biotherapeutics
EIGR Eiger BioPharmaceuticals
OYST Oyster Point Pharma
MIRM Mirum Pharmaceuticals
ADCT ADC Therapeutics
Price-To-Sales vs Peers: ADCT is good value based on its Price-To-Sales Ratio (4.2x) compared to the peer average (13.9x).
Price to Earnings Ratio vs Industry
How does ADCT's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: ADCT is good value based on its Price-To-Sales Ratio (4.2x) compared to the US Biotechs industry average (12.5x)
Price to Sales Ratio vs Fair Ratio
What is ADCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||4.2x|
|Fair PS Ratio||1.9x|
Price-To-Sales vs Fair Ratio: ADCT is expensive based on its Price-To-Sales Ratio (4.2x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).
Share Price vs Fair Value
What is the Fair Price of ADCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ADCT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ADCT's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.